Clinical Trials Logo

Long QT Syndrome clinical trials

View clinical trials related to Long QT Syndrome.

Filter by:

NCT ID: NCT04169100 Recruiting - Clinical trials for Rheumatoid Arthritis

Novel Form of Acquired Long QT Syndrome

Start date: September 28, 2011
Phase: Phase 4
Study type: Interventional

The goal of this study is to determine whether anti-Ro/SSA antibodies are associated with acquired QT prolongation in subjects with connective tissue disease. The investigators will investigate whether gender or race influence correlation between anti-Ro antibody status and prolonged QT interval and the role of inflammatory cytokines in association with anti-Ro antibodies and QT prolongation. The investigators propose to add an additional objective to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.

NCT ID: NCT03893734 Recruiting - EKG-QT Prolongation Clinical Trials

Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery

Start date: May 1, 2018
Phase: Phase 4
Study type: Interventional

A number of drugs used in the perioperative period may cause prolongation of the QT interval on the electrocardiogram (EKG). These drugs include inhalational agents, antiemetic agents, pain medications, and drugs used to reverse the effects of muscle relaxants. Approximately 80% of patients undergoing a general anesthetic will demonstrate significant prolongation of the QT interval on the EKG in the postanesthesia care unit (PACU) following surgery. The concern with QT interval prolongation is that it can result in a potentially lethal ventricular arrhythmia termed torsade des pointes. Despite the concurrent use of several of these medications in a typical general anesthetic, torsade des pointes is a rare event in the perioperative period. In the past decade, the use of intravenous methadone as part of a balanced anesthetic technique has increased significantly. A single dose provided at induction of anesthesia can provide prolonged (24-48 hours) relief from pain. Studies in patients receiving long-term treatment with methadone for addiction therapy or chronic pain have revealed that these patients are at risk for QT prolongation, torsade des pointe, and cardiac death. However, the effect of a single intravenous dose of methadone used in the operating room on the QT interval is uncertain. The aim of this randomized clinical trial is to compare the impact of methadone, when compared to the more commonly-used opioid hydromorphone, on QT prolongation measured with a 12-lead EKG in the PACU and on postoperative day 1. We hypothesize that methadone will not result in significant QT prolongation when used as part of a standardized general anesthetic.

NCT ID: NCT03775954 Recruiting - Clinical trials for Congenital Heart Disease

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

Start date: July 1, 2018
Phase:
Study type: Observational

Each year world-wide, 2.5 million fetuses die unexpectedly in the last half of pregnancy, 25,000 in the United States, making fetal demise ten-times more common than Sudden Infant Death Syndrome. This study will apply a novel type of non-invasive monitoring, called fetal magnetocardiography (fMCG) used thus far to successfully evaluate fetal arrhythmias, in order to discover potential hidden electrophysiologic abnormalities that could lead to fetal demise in five high-risk pregnancy conditions associated with fetal demise.

NCT ID: NCT02814981 Recruiting - Long QT Syndrome Clinical Trials

Hydroxyzine and Risk of Prolongation of QT Interval

HYDROXYZINE-QT
Start date: November 2015
Phase: N/A
Study type: Observational

On 04/30/2015, ANSM (the National Security Agency of Medicines and Health Products) shared an information for general practicioners, pediatricians, anesthesiologists, dermatologists, geriatricians, psychiatrists, community pharmacists and hospital about using hydroxyzine and the associated risk of QT prolongation on the electrocardiogram. Drugs containing hydroxyzine (the best known and most used is the Atarax®) are used in France in various indications including the treatment of minor manifestations of anxiety, premedication with general anesthesia and the symptomatic treatment of urticaria. A prolonged QT interval is a known risk factor for occurrence of torsades de pointes which can cause sudden death. We distinguish congenital and acquired long QT interval. The main cause of acquired long QT interval is a drug inhibition of the HERG potassium channel 1. Many drugs have been reported to cause sudden death by prolongation of QT interval and occurrence of torsades de pointes (macrolides, anti -arythmics, some psychotropic ...) The molecules based on hydroxyzine are known to be at risk of prolongation of QT interval in an experimental point of view but is not clearly identified in daily clinical practice. Pharmacology unit of Caen was the first to publish a case of QT prolongation under hydroxyzine . Through this publication, associated with other clinical data, hydroxyzine has been added to the list of drugs that can induce QT prolongation . Despite these recent recommendations, it does not seem that hydroxyzine prescriptions were changed daily and therefore the risk of QT prolongation persists. We therefore propose the study of the impact of hydroxyzine on the QT interval measured on the electrocardiogram in patients hospitalized at the University Hospital of Caen.

NCT ID: NCT02439658 Recruiting - Long QT Syndrome Clinical Trials

Genetics of QT Prolongation With Antiarrhythmics

DOFEGEN
Start date: January 2014
Phase:
Study type: Observational

To assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in patients being loaded with dofetilide or sotalol.

NCT ID: NCT02412709 Recruiting - Long QT Syndrome Clinical Trials

Long QT Syndrome Screening in Newborns

Start date: June 2015
Phase: Phase 2
Study type: Interventional

The purpose of this project is to test a new, very compact, 12-lead ECG device as a way to detect long QT syndrome (LQTS) in infants. The device -- called QTScreen -- was developed in Phase I of this project. In Phase II, the goals are to test the capacity of the device for LQTS screening in newborns and to obtain prevalence data on LQTS in California. The 4 main objectives are: 1. To validate the capacity of QTScreen for LQTS screening in newborns. 2. To determine the extent to which parents are able to use QTScreen on their babies at home. 3. To survey end-user experience and opinions. 4. To estimate the LQTS prevalence in California.

NCT ID: NCT02119091 Recruiting - Cardiac Toxicity Clinical Trials

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

Start date: April 2014
Phase: Phase 1
Study type: Interventional

A double-center, randomized, double-blinded, 2-way crossover, placebo-controlled Study: Comparison of single oral dose 400mg Moxifloxacin-induced QT prolongation between healthy Chinese volunteers and Caucasian Volunteers Study Objective:Primary Objective:To compare the difference of ΔΔQTcF (Baseline-adjusted, placebo-corrected effect on QTcF) between Chinese group and Caucasian group under the same exposure (Cmax) of Moxifloxacin.Secondary Objectives:1)To compare the difference of ΔΔQTcF, heart rate, PR, RR, QRS and Moxifloxacin plasma concentration between Chinese group and Caucasian group.2)To compare slopes of Moxifloxacin plasma Concentration/QTcF value between healthy Chinese volunteers and Caucasian Volunteers.

NCT ID: NCT02014961 Recruiting - Brugada Syndrome Clinical Trials

Worm Study: Modifier Genes in Sudden Cardiac Death

Start date: April 2015
Phase: N/A
Study type: Interventional

Quest for modifier genes associated with ventricular arrhythmias in presence of a cardiac sodium channel gene (SCN5A-delPhe1617) mutation.

NCT ID: NCT01745666 Recruiting - Clinical trials for Long QT Syndrome Type 1 or 2

Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients

QT long
Start date: May 2012
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the best stress exam to unmask long QT in patient with KCNQ1 or KCNH2 mutation without long QT interval in rest electrocardiogram.

NCT ID: NCT01728025 Recruiting - Clinical trials for Long QT Syndrome Type 3

Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

Start date: October 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.